Healthcare -
Biotechnology - NASDAQ - US
$ 24.81
-14.3 %
$ 1.47 B
Market Cap
-19.95
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Janux Therapeutics, Inc.
| Revenue | 10.6 M |
| Cost Of Revenue | 2.06 M |
| Gross Profit | 8.53 M |
| Operating Expenses | 109 M |
| Operating Income | -98.8 M |
| Other Expenses | -29.9 M |
| Net Income | -69 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 10.6 | 8.1 | 8.6 | 3.6 | 0 | 0 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 2.1 | 2.0 | 0.8 | 0.1 | 13 K | 6 K |
| Gross Profit | 8.5 | 6.1 | 7.8 | 3.5 | 13 K | 6 K |
| OPERATING INCOME | ||||||
| Operating Expenses | 109.4 | 81.1 | 75.7 | 36.6 | 4.8 | 3.8 |
| Selling, General and Administrative Expenses | 41.0 | 26.1 | 22.3 | 10.3 | 1.8 | 0.8 |
| Research and Development Expenses | 68.4 | 54.9 | 53.4 | 26.2 | 3.0 | 3.0 |
| Operating Income | (98.8) | (73.0) | (67.1) | (32.9) | (4.8) | (3.8) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 0 | 0 | 4.0 | 0 | 0.2 | 0.2 |
| Total Other Income | 29.9 | 14.7 | 4.0 | 0.3 | (1.9) | (0.2) |
| Pre-Tax Income | (69.0) | (58.3) | (63.1) | (32.7) | (6.8) | (4.0) |
| NET INCOME | ||||||
| Tax Provision | 0 | 0 | (8.9) | (0.1) | (1.5) | 0.2 |
| Net Income | (69.0) | (58.3) | (54.2) | (32.6) | (5.3) | (4.2) |
| EPS | 1.28 | 1.32 | 1.31 | 0.79 | 0.13 | 0.1 |